Biocept liquid biopsy improves accuracy for monitoring metastatic breast cancer

 

• Biocept climbs (BIOC +12.8%) on market open, on announcement of results from a prospective study showing that the company's Target Selector liquid biopsy was highly accurate in monitoring HER2 alterations in patients with metastatic breast cancer.
• The company says that Target Selector has been shown to be a highly sensitive blood-based testing method for identifying changes in HER2 status, and is less invasive, more time & cost efficient compared to tissue biopsy.
• Also, results from a study analyzing cerebrospinal fluid samples announced last month, indicated that Biocept's Target Selector CSF assays are a viable and sensitive platform for circulating tumor cell detection and molecular analysis compared to the current standard of care.
• https://seekingalpha.com/news/3643314-biocepts-liquid-biopsy-shows-improved-accuracy-for-monitoring-progression-of-metastatic